David R. Gandara

TL;DR: Combination MK-2206 and erlotinib met its primary endpoint in erlot inib-pretreated patients with EGFR wild-type NSCLC, and activity was seen in EGFR-mutated NSCLc, although activity did not exceed a priori estimates.

TL;DR: It was concluded that detection of tumor DNA in plasma is feasible using molecular techniques and that this approach shows promise for monitoring patient response to therapy.

TL;DR: Sequential therapy, as used in this study, resulted in comparable efficacy to previous Southwest Oncology Group trials of two drug combinations in this population; however, it failed to meet criteria for further study.

TL;DR: It is found that oxaliplatin was well tolerated at its recommended dose and schedule of 130 mg/m(2) every 21 days in patients with all levels of liver dysfunction, and that there was no apparent alteration in the clearance of either total or ultrafilterable platinum species from plasma, even in Patients with severe hepatic functional abnormalities.

TL;DR: It is concluded that for each drug there is a plateau in therapeutic efficacy at a definable dose level above which further dose escalation does not improve outcome and a single dose is as effective as multiple doses or continuous infusion, and emerging data demonstrate that the oral route is equally efficacious as the intravenous route of administration, even with highly emetogenic chemotherapy.